*tbo-filgrastim, filgrastim-tbo, filgrastim-sndz, sndz-filgrastim
Drug Name | Form | Strength | Formulary Unrestricted | Formulary Restricted | Non-Formulary | Interchange |
---|---|---|---|---|---|---|
Neupogen | SOLUTION, INJECTABLE | 480 mcg/1.6 mL, 300 mcg/mL | ||||
Neupogen | SOLUTION, INJECTABLE | 600 mcg/mL | ||||
Granix | SOLUTION, SUBCUTANEOUS | 300 mcg/0.5 mL, 480 mcg/0.8 mL | ||||
Nivestym | SOLUTION, SUBCUTANEOUS | 300 mcg/0.5 mL, 480 mcg/0.8 mL | ||||
Releuko | SOLUTION, SUBCUTANEOUS | 300 mcg/0.5 mL, 480 mcg/0.8 mL | ||||
Zarxio | SOLUTION, SUBCUTANEOUS | 300 mcg/0.5 mL, 480 mcg/0.8 mL |
New FDA Indications
Neupogen, Zarxio, Nivestym, Releuko, and Granix have all been classified as therapeutically equivalent and should be interchanged in a 1:1 ratio at the same dosing interval based on the lowest cost agent at the time.
Nivestym is the preferred product for adult and pediatric inpatient and outpatient use (updated March 2024)
Dose rounding (Adults):
Reviewed: 26 January 2016, 25 Sept 2018 (Nivestym), Sept. 2022 (Releuko)
Updated: December 2022 (Dose Rounding)
Filgrastim-pbbk (Releuko)